Gelmicin: Uses, Presentation, Application, Precautions, Adverse Reactions, Contraindications and Interactions

It is a topical cream or spray for adults that can help relieve and improve some skin conditions.

For information, the term “topical” means that the application of the drug or treatment is on the outer surface of the body (for example, on the skin or mucous membranes).

Uses of gelmicin cream and spray

Gelmicin is a medicine to apply exclusively to the skin to treat conditions such as:

  • Chronic dermatitis of the extremities.
  • Eritrasma, balanopostitis.
  • Herpes zoster.
  • Eczematoid dermatitis.
  • Contact dermatitis.
  • Follicular dermatitis.
  • Keratosis .
  • Paronychia .
  • Anal itching
  • Intertrigo.
  • Impetigo.
  • Neurodermatitis.
  • Angular stomatitis.
  • Photosensitivity dermatitis.
  • Liquefied inguinal dermatophytosis.
  • He had infections such as: he had pedis, he had cruris and he had corporis.

Presentation of gelmicin and active ingredients

This medicine has a presentation of a tube that contains 40 g of 1.41 oz.

The active ingredients of this medicine are:

  • Dipropionato de betametasona: 0.05.
  • Gentamicin sulfate: 0.10 g.
  • Clotrimazol: 1.00 g.

It also contains mineral oil, white vaseline and cetostearyl alcohol for its oily phase based on emulsion and chlorocresol as a preservative. Gelmycin cream contains white petroleum jelly as its excipient.

Gelmicin cream dosage

It should be applied to the affected area two or three times a day, or as prescribed by the doctor. The frequency of application should be determined by the doctor according to the severity of the condition.

Duration of treatment : The duration of therapy varies depending on the extent and location of the disease and the response of the patient. In cases of tinea pedia, a longer treatment (2-4 weeks) may be necessary.

However, if clinical improvement is not achieved within three to four weeks, the diagnosis should be reviewed.
The cream should be allowed to absorb or sometimes covered for a longer absorption.

Another presentation of gelmicin (spray)

Gelmicin also comes in a spray form.

Gelmicin spray, 0.05% is for topical use. Each gram of gelmicin (betamethasone dipropionate) spray contains:

  • 0.643 mg of gelmicin (betamethasone dipropionate) USP (equivalent to 0.5 mg of betamethasone) in a slightly thick, white to off-white oil-in-water emulsion.

Dosage and administration of gelmicin spray

  • Shake well before use.
  • Apply gelmicin (betamethasone dipropionate) spray to affected skin areas twice a day and rub in gently.
  • Use gelmicin (betamethasone dipropionate) spray for up to 4 weeks of treatment. Treatment beyond 4 weeks is not recommended.
  • Discontinue gelmycin (betamethasone dipropionate) spray when control is achieved.
  • Do not use if there is atrophy at the treatment site.
  • Do not cover, cover, or cover the treated area of ​​skin unless directed by a doctor.
  • Avoid use on the face, scalp, armpit, groin, or other intertriginous areas.
  • Gelmicin (betamethasone dipropionate) spray is for topical use only. Not for oral, ophthalmic, or intravaginal use.
  • Apply to the affected areas of the skin twice a day. Rub gently.
  • Use gelmicin (betamethasone dipropionate) spray for up to 4 weeks and no longer.
  • Stop treatment when control is achieved.
  • Do not use if there is atrophy at the treatment site.
  • Do not use with occlusive dressings unless directed by a physician.
  • Avoid use on the face, scalp, armpit, groin, or other intertriginous areas.
  • Not for oral, ophthalmic, or intravaginal use.

Cautions and warnings

  • Gelmicin can produce reversible suppression of the HPA axis with the possibility of glucocorticosteroid insufficiency during or after treatment.
  • Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus may be the result of systemic absorption of topical corticosteroids.
  • The use of topical corticosteroids may require periodic evaluation for HPA axis suppression. Modify usage if HPA axis suppression develops.
  • High-potency corticosteroids, large treatment surface areas, prolonged use, use of occlusive bandages, altered skin barrier, liver failure, and youth can predispose patients to suppression of the HHA axis.
  • Pediatric patients may be more susceptible to systemic toxicity when treated with topical corticosteroids.

Gelmicin adverse reactions

The most common adverse reactions are application site reactions, including:

  • Itching, burning and / or burning.
  • Pain.
  • Atrophy.

Use in specific populations

Pregnancy

Pregnancy category C.

There are no adequate and well-controlled studies in pregnant women. Gelmicin cream or spray should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Gelmycin (betamethasone dipropionate) has been shown to be teratogenic in rabbits when administered intramuscularly at a dose of 0.05 mg / kg. The abnormalities observed included umbilical hernias, cephalocele, and cleft palate.

Nursing mothers

Systemically administered corticosteroids appear in human milk and can suppress growth, interfere with endogenous corticosteroid production, or cause other adverse effects.

It is not known whether topical administration of corticosteroids can result in sufficient systemic absorption to produce detectable amounts in human milk.

Because many drugs are excreted in human milk, caution should be exercised when gelmycin (betamethasone dipropionate) is administered to a nursing woman.

Pediatric use

The safety and efficacy of Gelmicin have not been studied in patients younger than 18 years of age; therefore, its use in pediatric patients is not recommended.

Due to a higher ratio of skin surface area to body mass, pediatric patients are at increased risk of systemic toxicity, including HPA axis suppression and adrenal insufficiency, when treated with topical medications.

Uncommon systemic effects such as Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients, especially those with prolonged exposure to large doses of high-potency topical corticosteroids.

Local adverse reactions, including skin atrophy, have also been reported with the use of topical corticosteroids in pediatric patients.

Geriatric use

The clinical studies of gelmicin (betamethasone dipropionate) cream or spray did not include a sufficient number of subjects who were 65 years of age or older to determine whether they respond differently from younger subjects.

Gelmicin contraindications

This drug is contraindicated in patients with a history of sensitivity reactions to betamethasone, gentamicin, clotrimazole or any of the components of the drug.

Topical corticosteroids are contraindicated in vaccinia, chickenpox, and tuberculosis of the skin.

Gelmicin interactions

Concomitant use of phenobarbital, phenytoin, rifampin or ephedrine can improve the metabolism of corticosteroids, reducing their therapeutic effects.

Patients receiving both a corticosteroid and an estrogen should be watched for excessive effects of corticosteroids.

There are other interactions for which you should inform your doctor about other medications that you have prescribed.

Storage

Store below 30 degrees C. It should not be frozen.